Veracyte, Inc. (VCYT)
VCYT Stock Price Chart
Explore Veracyte, Inc. interactive price chart. Choose custom timeframes to analyze VCYT price movements and trends.
VCYT Company Profile
Discover essential business fundamentals and corporate details for Veracyte, Inc. (VCYT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Oct 2013
Employees
824.00
Website
https://www.veracyte.comCEO
Marc A. Stapley
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Financial Timeline
Browse a chronological timeline of Veracyte, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is $0.32, while revenue estimate is $124.62M.
Earnings released on 6 Aug 2025
EPS came in at $0.44 surpassing the estimated $0.31 by +41.94%, while revenue for the quarter reached $130.16M , beating expectations by +4.67%.
Earnings released on 7 May 2025
EPS came in at $0.31 surpassing the estimated $0.20 by +55.00%, while revenue for the quarter reached $114.47M , beating expectations by +3.16%.
Earnings released on 24 Feb 2025
EPS came in at $0.36 surpassing the estimated $0.10 by +260.00%, while revenue for the quarter reached $118.63M , beating expectations by +7.14%.
Earnings released on 6 Nov 2024
EPS came in at $0.19 surpassing the estimated $0.03 by +603.70%, while revenue for the quarter reached $115.86M , missing expectations by -0.71%.
Earnings released on 6 Aug 2024
EPS came in at $0.30 surpassing the estimated $0.05 by +530.78%, while revenue for the quarter reached $114.43M , beating expectations by +14.12%.
Earnings released on 7 May 2024
EPS came in at -$0.02 surpassing the estimated -$0.19 by +89.47%, while revenue for the quarter reached $96.84M , beating expectations by +3.72%.
Earnings released on 22 Feb 2024
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%, while revenue for the quarter reached $98.20M , beating expectations by +6.78%.
Earnings released on 7 Nov 2023
EPS came in at -$0.03 surpassing the estimated -$0.16 by +81.25%, while revenue for the quarter reached $90.11M , beating expectations by +6.79%.
Earnings released on 8 Aug 2023
EPS came in at -$0.12 surpassing the estimated -$0.16 by +25.00%, while revenue for the quarter reached $90.32M , beating expectations by +8.70%.
Earnings released on 4 May 2023
EPS came in at -$0.11 surpassing the estimated -$0.14 by +21.43%, while revenue for the quarter reached $82.42M , beating expectations by +8.72%.
Earnings released on 22 Feb 2023
EPS came in at -$0.05 surpassing the estimated -$0.15 by +66.67%, while revenue for the quarter reached $80.30M , beating expectations by +8.59%.
Earnings released on 2 Nov 2022
EPS came in at -$0.12 surpassing the estimated -$0.24 by +50.00%, while revenue for the quarter reached $75.59M , beating expectations by +13.83%.
Earnings released on 2 Aug 2022
EPS came in at -$0.13 surpassing the estimated -$0.21 by +38.10%, while revenue for the quarter reached $72.86M , beating expectations by +7.02%.
Earnings released on 3 May 2022
EPS came in at -$0.20 surpassing the estimated -$0.23 by +13.04%, while revenue for the quarter reached $67.78M , beating expectations by +9.48%.
Earnings released on 28 Feb 2022
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%, while revenue for the quarter reached $67.34M , beating expectations by +7.71%.
Earnings released on 9 Nov 2021
EPS came in at -$0.13 surpassing the estimated -$0.14 by +7.14%, while revenue for the quarter reached $60.37M , beating expectations by +12.55%.
Earnings released on 29 Jul 2021
EPS came in at -$0.13 surpassing the estimated -$0.25 by +48.00%, while revenue for the quarter reached $55.11M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%, while revenue for the quarter reached $36.70M , beating expectations by +14.59%.
Earnings released on 17 Feb 2021
EPS came in at -$0.14 falling short of the estimated -$0.09 by -55.56%, while revenue for the quarter reached $34.54M , beating expectations by +8.77%.
Earnings released on 2 Nov 2020
EPS came in at -$0.08 surpassing the estimated -$0.18 by +55.56%, while revenue for the quarter reached $31.12M , missing expectations by -61.90%.
VCYT Stock Performance
Access detailed VCYT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.